Evidence mapPaperPMID 40424496Full record

ArticleJournal of the National Cancer Institute2025

Risk of aggressive prostate cancer with successive generations in the US among Latino men.

Fei Chen, Adelynn Paik, Xin Sheng, Iona Cheng, Salma Shariff-Marco, Lynne R Wilkens, Loïc Le Marchand, David V Conti, Christopher A Haiman, Veronica Wendy Setiawan

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fei ChenDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0002-1679-9932
Adelynn PaikDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0009-0003-5175-665X
Xin ShengCenter for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0002-6844-2740
Iona ChengDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States.ORCID 0000-0003-4132-2893
Salma Shariff-MarcoDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States.ORCID 0000-0002-2541-3333
Lynne R WilkensEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States.ORCID 0000-0001-8408-4536
Loïc Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States.ORCID 0000-0001-5013-980X
David V ContiDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0002-2941-7833
Christopher A HaimanDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0002-0097-9971
Veronica Wendy SetiawanDepartment of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.ORCID 0000-0001-9239-5692

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · UNIVERSITY OF HAWAII AT MANOA · 1996 to 2025
$13.6M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · UNIVERSITY OF HAWAII AT MANOA · 2025 to 2025
$4.9M
National Institute of HealthNational Institute of Health U01CA164973NCI NIH HHS P30 CA071789NCI NIH HHS U01 CA164973
6 · The paper itself

Abstract

backgroundUS-born Latino men have a higher incidence of prostate cancer than foreign-born Latino men. It was not clear whether these increases were exclusively due to increased detection of prostate cancer in the United States, changes in risk factors of prostate cancer, or a combination of both.

methodsIn the Multiethnic Cohort we evaluated the association between generational status and risk of prostate cancer in 19 597 Latino men, adjusting for demographic and lifestyle factors and individual- and neighborhood-level socioeconomic status, as well as history of prostate-specific antigen screening. Additional adjustments on polygenic risk score and genetic ancestry were included in the sensitivity analysis in the biorepository cohort with genetic data.

resultsThis analysis included 10 241 first-generation, 4610 second-generation, and 4746 third-generation Latino men, among whom 2366 were diagnosed with prostate cancer during an average of 19.2 years of follow-up. After adjusting for covariates, we observed no association between generational status and risk of overall, localized, or low-grade prostate cancer. A per generation increase was statistically significantly associated with a 13%-15% elevated risk of high-grade, advanced, or aggressive prostate cancer. These associations with aggressive forms of prostate cancer remained statistically significant in the biorepository cohort with additional adjustment on polygenic risk score and genetic ancestry.

conclusionsSuccessive generations in the United States were associated with an increased risk of aggressive forms of prostate cancer among Latino men, and the observed increases cannot be explained by differences in genetic susceptibility, ancestry, prostate-specific antigen screening, lifestyle, or socioeconomic status factors. Further investigations are needed to identify additional factors that contribute to this increased risk.

Indexed as

Hispanic or LatinoProstatic NeoplasmsAdultAgedCohort StudiesHumansIncidenceMaleMiddle AgedProstate-Specific AntigenRisk FactorsUnited StatesProstate-Specific Antigen

Identifiers

PMID40424496
PMCPMC12342825

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.